NICE Recommends Vutrisiran for Transthyretin-Related Amyloidosis

The U.K.’s National Institute for Health Care and Excellence (NICE) has recommended vutrisiran (branded as Amvuttra and Alnylam) for use by the National Health Service (NHS) to treat hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

NICE said vutrisiran is an improvement over the standard treatment of patisiran as vutrisiran can be injected under the skin. Patisiran must be injected in a vein by a healthcare professional, which increases the cost of using the drug.

Evidence from a clinical trial and an indirect comparison shows that vutrisiran works as well as patisiran, NICE said.

Vutrisiran is a small interfering RNA that blocks with the expression of the transthyretin gene. It was approved in the U.S. in June of last year and in the EU in September.